Butalbital, Acetaminophen And Caffeine
NDC Package 16590-581-72

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Butalbital, Acetaminophen And Caffeine is iNDICATIONS AND USAGEButalbital, Acetaminophen and Caffeine Tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Marketed by Stat Rx Usa Llc, this product is identified by NDC 16590-581 and is authorized under FDA application ANDA040513.

Identification & Billing

NDC Package Code
16590-581-72
Package Description
120 TABLET in 1 BOTTLE
Product Code
16590-581
11-Digit Billing Format
16590058172
RxNorm Crosswalk
  • RxCUI: 240093 - butalbital 50 MG / acetaminophen 500 MG / caffeine 40 MG Oral Tablet
  • RxCUI: 240093 - acetaminophen 500 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet
  • RxCUI: 240093 - APAP 500 MG / butalbital 50 MG / caffeine 40 MG Oral Tablet

Clinical Specifications

Proprietary Name
Butalbital, Acetaminophen And Caffeine Plus
Dosage Form
-
Usage Information
INDICATIONS AND USAGEButalbital, Acetaminophen and Caffeine Tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

Regulatory & Marketing

Labeler Name
Stat Rx Usa Llc
FDA Application #
ANDA040513
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-25-2003
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (16590-581). Click a package code to view its specific billing and regulatory data.

16590-581-30
30 TABLET in 1 BOTTLE
16590-581-60
60 TABLET in 1 BOTTLE
16590-581-90
90 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-581-72 identifies a specific commercial package of 120 tablet in 1 bottle of Butalbital, Acetaminophen And Caffeine Plus, labeled by Stat Rx Usa Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa Llc on August 25, 2003. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590058172. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-581-72
11-Digit CMS (5-4-2)
16590-0581-72

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.